Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Analytical Performance of Modified Anti-FXa Assays for Andexanet Alfa-Containing Plasma Samples on the ACL TOP/TOP 50 Coagulation Analyzers

Anuja Khan, PhD, Krisjela Shishko, BS, Ryan Marett, BS, Sam Arcidiacono, BS, MT(ASCP), Vy Nguyen, BS, Genmin Lu, Khanh Bui, BS, Pamela B. Conley, PhD, Anne Winkler, MD

Blood (2020) 136 (Supplement 1): 5.

https://doi.org/10.1182/blood-2020-141006

Published: 2020

Journal Articles

Validation of a Modified Anti-FXa Assay on STA-Compact Analyzer for Measuring FXa Inhibitor Levels in the Presence of Andexanet Alfa

Juan Cardenas, PhD, Jayaprakash Kotha, PhD MBBS, Genmin Lu, Pamela B. Conley, PhD, Matthieu Bourdin, Tristan Herve, Lisa K. Jennings, PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-140988

Published: 2020

Journal Articles

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Steven M. Horwitz, MD, Tatyana A. Feldman, MD, Brian T. Hess, MD, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Javier Munoz, MD MS, FACP, Manish R. Patel, MD, Tycel J. Phillips, MD, Stephen D. Smith, MD, Sonali M. Smith, MD, Ryan A. Wilcox, MD PhD, Matt R. Birrell, Janet M. Leeds, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, Gregory P. Coffey, PhD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 466.

https://doi.org/10.1182/blood-2019-123986

Published: 2019

Journal Articles

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab

Stephen D. Smith, MD, Javier Munoz, MD MS, FACP, Don Stevens, MD, Sonali M. Smith, MD, Tatyana A. Feldman, MD, J Christine Ye, MDMSc, Sven de Vos, MD PhD, Brian T. Hess, MD, Carole B. Miller, MD, James L. Khatcheressian, MD, Matt R. Birrell, Janet M. Leeds, PhD, Gregory P. Coffey, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 3981.

https://doi.org/10.1182/blood-2019-124231

Published: 2019

Journal Articles

Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors

Michiel Coppens, MD, Lizhen Xu, PhD, Roisin Bavalia, MD, Saskia Middeldorp, MD PhD, Peter Verhamme, MD PhD, John W. Eikelboom, MBBS, MSc, FRACP, FRCPA, Mark Crowther, MD, Genmin Lu, Patrick Yue, MD, Pamela B. Conley, PhD, Stuart J. Connolly, MD MSc, FRCPC

Blood (2019) 134 (Supplement_1): 711.

https://doi.org/10.1182/blood-2019-124596

Published: 2019

Journal Articles

Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By Andexanet Alfa and "Work Around" By PCCs

Genmin Lu, Joyce P. Lin, BS, Khanh Bui, BS, John T. Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2019) 134 (Supplement_1): 713.

https://doi.org/10.1182/blood-2019-124864

Published: 2019

Journal Articles

Modified Anti-FXa Assays for Measuring the Residual Activity of Apixaban and Rivaroxaban in Andexanet Alfa-Containing Samples on the ACL TOP Family ® Coagulation Analyzers

Anuja Khan, PhD, Krisjela Shishko, BS, Sam Arcidiacono, BS, Khanh Bui, BS, Genmin Lu, Pamela B. Conley, PhD, Anne Winkler, MD

Blood (2019) 134 (Supplement_1): 1153.

https://doi.org/10.1182/blood-2019-126254

Published: 2019

Journal Articles

Comparison of Second and First Generation of Andexanet Alfa in a Porcine Polytrauma Model with Apixaban Anticoagulation

Oliver Grottke, MD PhD MPH, Necib Akman, MD, Till Braunschweig, MD, Pamela B. Conley, PhD, Rolf Rossaint, MD

Blood (2018) 132 (Supplement 1): 3778.

https://doi.org/10.1182/blood-2018-99-114542

Published: 2018

Journal Articles

Reversal of Apixaban Anticoagulation with Reduced Doses of Andexanet Alfa in a Porcine Polytrauma Model

Oliver Grottke, MD PhD MPH, Necib Akman, MD, Till Braunschweig, MD, Pamela B. Conley, PhD, Rolf Rossaint, MD

Blood (2018) 132 (Supplement 1): 2456.

https://doi.org/10.1182/blood-2018-99-114426

Published: 2018

Journal Articles

The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2018-99-119944

Published: 2018

Journal Articles

Physiologically Based Pharmacokinetic (PBPK) Modeling for Betrixaban and the Impact of P-Glycoprotein Inhibition on Betrixaban Pharmacokinetics

Janet M. Leeds, PhD, Alice Ke, Karen Rowland Yeo, John T Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2017) 130 (Supplement 1): 3663.

https://doi.org/10.1182/blood.V130.Suppl_1.3663.3663

Published: 2017

Journal Articles

Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B Cell Malignancies: Results from a Phase I Dose Escalation Study

Gregory P. Coffey, PhD, Jiajia Feng, MD, Andreas Betz, PhD, Anjali Pandey, PhD, Matt Birrell, B.S., Janet M. Leeds, PhD, Kenneth Der, PhD, Sabah Kadri, PhD, Pin Lu, PhD, Jeremy Segal, PhD, Lynn Wang, MD PhD, Glenn Michelson, MD, John T Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2017) 130 (Supplement 1): 2782.

https://doi.org/10.1182/blood.V130.Suppl_1.2782.2782

Published: 2017

Journal Articles

Effect of Andexanet-TFPI Interaction on in Vitro Thrombin Formation and Coagulation Markers in the TF-Pathway

Genmin Lu, Joyce P Lin, BS, John T. Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2017) 130 (Supplement 1): 629.

https://doi.org/10.1182/blood.V130.Suppl_1.629.629

Published: 2017

Journal Articles

Genetic or CD40L-Mediated Loss of Iκbα Is Associated with Resistance to the Dual SYK/JAK Inhibitor Cerdulatinib in DLBCL Cell Lines

Greg P Coffey, PhD, Jiajia Feng, MD, Sabah Kadri, PhD, Y. Lynn Wang, MD PhD, Pin Lu, PhD, Shruti Sharma, PhD, Jeremy Segal, PhD, Glenn Michelson, MD, Anjali Pandey, PhD, John T. Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2016) 128 (22): 2768.

https://doi.org/10.1182/blood.V128.22.2768.2768

Published: 2016

Journal Articles

Reversal of Betrixaban-Induced Anticoagulation in Healthy Volunteers By Andexanet Alfa

Mark Crowther, MD, Genmin Lu, PhD, Janet M. Leeds, PhD, Joyce Lin, BS, Pamela B. Conley, PhD, Alexander Gold, MD, Stuart J. Connolly, MD, John T. Curnutte, MD PhD

Blood (2016) 128 (22): 143.

https://doi.org/10.1182/blood.V128.22.143.143

Published: 2016

Journal Articles

Regulation of B-Cell Receptor Signalling By the Tumour Microenvironment in Chronic Lymphocytic Leukemia (CLL) and Its Impact on Adhesion and miRNA Expression

Matthew D Blunt, PhD, Rachel Dobson, BSc(Hons), Lindsay D Smith, PhD, Jonathan C. Strefford, Pamela B. Conley, PhD, Anjali Pandey, PhD, Andrew J Davies, FRCP PhD, Peter M Johnson, MA, MD, Graham Packham, PhD, Freda K Stevenson, DPhil, Francesco Forconi, MD DM, PhD FRCPath, Greg P Coffey, PhD, Andrew J Steele, PhD

Blood (2016) 128 (22): 351.

https://doi.org/10.1182/blood.V128.22.351.351

Published: 2016

Journal Articles

Andexanet Alfa, a Universal Antidote Under Development for Factor Xa Inhibitors, Reverses Rivaroxaban-Induced Inhibition of Thrombin Generation Initiated By the Intrinsic Coagulation Pathway Independent of TFPI

Genmin Lu, PhD, Joyce Lin, BS, John T. Curnutte, MDPhD, Pamela B. Conley, PhD

Blood (2016) 128 (22): 3831.

https://doi.org/10.1182/blood.V128.22.3831.3831

Published: 2016

Journal Articles

Andexanet Alfa Reverses Anticoagulation Effects of Enoxaparin and Associated Bleeding in a Rabbit Acute Hemorrhage Model

Polly Pine, PhD, Genmin Lu, PhD, Deogracias Canivel, Pratikhya Pratikhya, BS, MSc, Francis DeGuzman, PhD, Mark Karbarz, PhD, Kentaro Takeda, BS, John Malinowski, PhD, Janet M. Leeds, PhD, John T. Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2016) 128 (22): 1445.

https://doi.org/10.1182/blood.V128.22.1445.1445

Published: 2016

Journal Articles

Pharmacokinetic and Pharmacodynamic (PKPD) Modeling to Determine the Andexanet Alfa Dose to Reverse the Anticoagulant Activity of Direct Fxa Inhibitors

Leeds Janet, PhD, Genmin Lu, PhD, John T. Curnutte, MDPhD, Pamela B. Conley, PhD, Jaap W. Mandema, PhD

Blood (2015) 126 (23): 1135.

https://doi.org/10.1182/blood.V126.23.1135.1135

Published: 2015

Journal Articles

Reversal of Heparin-Induced Anticoagulation By Andexanet Alfa, a Universal Antidote for Factor Xa Inhibitors

Genmin Lu, PhD, Joyce Lin, BS, John T. Curnutte, MDPhD, Pamela B. Conley, PhD

Blood (2015) 126 (23): 2329.

https://doi.org/10.1182/blood.V126.23.2329.2329

Published: 2015

NARROW

Analytical Performance of Modified Anti-FXa Assays for Andexanet Alfa-Containing Plasma Samples on the ACL TOP/TOP 50 Coagulation Analyzers

Validation of a Modified Anti-FXa Assay on STA-Compact Analyzer for Measuring FXa Inhibitor Levels in the Presence of Andexanet Alfa

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab

Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors

Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By Andexanet Alfa and "Work Around" By PCCs

Modified Anti-FXa Assays for Measuring the Residual Activity of Apixaban and Rivaroxaban in Andexanet Alfa-Containing Samples on the ACL TOP Family ® Coagulation Analyzers

Comparison of Second and First Generation of Andexanet Alfa in a Porcine Polytrauma Model with Apixaban Anticoagulation

Reversal of Apixaban Anticoagulation with Reduced Doses of Andexanet Alfa in a Porcine Polytrauma Model

The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Physiologically Based Pharmacokinetic (PBPK) Modeling for Betrixaban and the Impact of P-Glycoprotein Inhibition on Betrixaban Pharmacokinetics

Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B Cell Malignancies: Results from a Phase I Dose Escalation Study

Effect of Andexanet-TFPI Interaction on in Vitro Thrombin Formation and Coagulation Markers in the TF-Pathway

Genetic or CD40L-Mediated Loss of Iκbα Is Associated with Resistance to the Dual SYK/JAK Inhibitor Cerdulatinib in DLBCL Cell Lines

Reversal of Betrixaban-Induced Anticoagulation in Healthy Volunteers By Andexanet Alfa

Regulation of B-Cell Receptor Signalling By the Tumour Microenvironment in Chronic Lymphocytic Leukemia (CLL) and Its Impact on Adhesion and miRNA Expression

Andexanet Alfa, a Universal Antidote Under Development for Factor Xa Inhibitors, Reverses Rivaroxaban-Induced Inhibition of Thrombin Generation Initiated By the Intrinsic Coagulation Pathway Independent of TFPI

Andexanet Alfa Reverses Anticoagulation Effects of Enoxaparin and Associated Bleeding in a Rabbit Acute Hemorrhage Model

Pharmacokinetic and Pharmacodynamic (PKPD) Modeling to Determine the Andexanet Alfa Dose to Reverse the Anticoagulant Activity of Direct Fxa Inhibitors

Reversal of Heparin-Induced Anticoagulation By Andexanet Alfa, a Universal Antidote for Factor Xa Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only